BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31822499)

  • 21. Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18.
    Ma Z; Li W; Yoshiya S; Xu Y; Hata M; El-Darawish Y; Markova T; Yamanishi K; Yamanishi H; Tahara H; Tanaka Y; Okamura H
    Clin Cancer Res; 2016 Jun; 22(12):2969-80. PubMed ID: 26755531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
    Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
    Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.
    Zhang S; Bai X; Shan F
    Int Immunopharmacol; 2020 Mar; 80():106247. PubMed ID: 32007710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
    Ren S; Tian Q; Amar N; Yu H; Rivard CJ; Caldwell C; Ng TL; Tu M; Liu Y; Gao D; Ellison K; Suda K; Rozeboom L; Rivalland G; Mitchell P; Zhou C; Hirsch FR
    Lung Cancer; 2018 Nov; 125():115-120. PubMed ID: 30429008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cationic liposome mediated delivery of FUS1 and hIL-12 coexpression plasmid demonstrates enhanced activity against human lung cancer.
    Ren J; Yu C; Wu S; Peng F; Jiang Q; Zhang X; Zhong G; Shi H; Chen X; Su X; Luo X; Zhu W; Wei Y
    Curr Cancer Drug Targets; 2014; 14(2):167-80. PubMed ID: 24410728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.
    Liu H; Kuang X; Zhang Y; Ye Y; Li J; Liang L; Xie Z; Weng L; Guo J; Li H; Ma F; Chen X; Zhao S; Su J; Yang N; Fang F; Xie Y; Tao J; Zhang J; Chen M; Peng C; Sun L; Zhang X; Liu J; Han L; Xu X; Hung MC; Chen X
    Cancer Cell; 2020 Mar; 37(3):324-339.e8. PubMed ID: 32183950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth.
    Chung JS; Tamura K; Cruz PD; Ariizumi K
    J Invest Dermatol; 2014 Nov; 134(11):2784-2794. PubMed ID: 24936834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
    Tzeng A; Diaz-Montero CM; Rayman PA; Kim JS; Pavicic PG; Finke JH; Barata PC; Lamenza M; Devonshire S; Schach K; Emamekhoo H; Ernstoff MS; Hoimes CJ; Rini BI; Garcia JA; Gilligan TD; Ornstein MC; Grivas P
    Target Oncol; 2018 Oct; 13(5):599-609. PubMed ID: 30267200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I Trial of Intratumoral Injection of
    Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
    Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunotherapy response modeling by ex-vivo organ culture for lung cancer.
    Kamer I; Bab-Dinitz E; Zadok O; Ofek E; Gottfried T; Daniel-Meshulam I; Hout-Siloni G; Ben Nun A; Barshack I; Onn A; Bar J
    Cancer Immunol Immunother; 2021 Aug; 70(8):2223-2234. PubMed ID: 33484295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
    Goodman AM; Kato S; Bazhenova L; Patel SP; Frampton GM; Miller V; Stephens PJ; Daniels GA; Kurzrock R
    Mol Cancer Ther; 2017 Nov; 16(11):2598-2608. PubMed ID: 28835386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
    Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
    J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
    Markowitz GJ; Havel LS; Crowley MJ; Ban Y; Lee SB; Thalappillil JS; Narula N; Bhinder B; Elemento O; Wong ST; Gao D; Altorki NK; Mittal V
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Hirashima T; Kanai T; Suzuki H; Yoshida H; Matsushita A; Kawasumi H; Samejima Y; Noda Y; Nasu S; Tanaka A; Morishita N; Hashimoto S; Kawahara K; Tamura Y; Okamoto N; Tanaka T
    Anticancer Res; 2019 Nov; 39(11):6231-6240. PubMed ID: 31704852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
    Sakata Y; Kawamura K; Ichikado K; Shingu N; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Iio M; Sekido Y; Nakano A; Sakagami T
    Lung Cancer; 2019 Apr; 130():159-161. PubMed ID: 30885338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
    Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
    Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Knockout of MDA-9/Syntenin (SDCBP) expression in the microenvironment dampens tumor-supporting inflammation and inhibits melanoma metastasis.
    Das SK; Guo C; Pradhan AK; Bhoopathi P; Talukdar S; Shen XN; Emdad L; Subler MA; Windle JJ; Sarkar D; Wang XY; Fisher PB
    Oncotarget; 2016 Jul; 7(30):46848-46861. PubMed ID: 27341128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status of immune checkpoint inhibition in early-stage NSCLC.
    Vansteenkiste J; Wauters E; Reymen B; Ackermann CJ; Peters S; De Ruysscher D
    Ann Oncol; 2019 Aug; 30(8):1244-1253. PubMed ID: 31143921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.